April 28, 2020 / 11:49 AM / a month ago

BRIEF-Apellis Reports Analysis From Phase 1B Geographic Atrophy Study

April 28 (Reuters) - Apellis Pharmaceuticals Inc:

* APELLIS REPORTS ANALYSIS FROM PHASE 1B GEOGRAPHIC ATROPHY STUDY

* APELLIS - NO CASES OF INFLAMMATION OBSERVED AFTER 12 MONTHS WITH PHASE 3 FORMULATION OF PEGCETACOPLAN IN PATIENTS WITH ADVANCED GEOGRAPHIC ATROPHY

* APELLIS PHARMACEUTICALS INC - PHASE 3 DERBY AND OAKS STUDIES EXPECTED TO FULLY ENROLL IN H1 OF 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below